Table 3 Approved therapies based on PD-1/PD-L1 blockade

Atezolizumab

 Melanoma

IMspire150

III

–

Atezolizumab + Cobitinib + Verofini vs. Placebo + Cobitinib + Verofini

15.1 vs. 10.6

–

–

DOR: 21.0 vs. 12.6 months

 NSCLC

POPLAR

II

287

Atezolizumab vs. Docetaxel

–

12.6 vs. 9.7

15

–

OAK

III

1125

Atezolizumab vs. Docetaxel

–

13.8 vs. 9.6

–

 UC

IMvigor210

II

310

Atezolizumab

2.1

7.9

15

–

IMvigor211

III

931

Atezolizumab vs. ICC

–

11.1 vs. 10.6

23 vs. 22

DOR: 15.9 vs. 8.3 months

 CRC

Bendell et al

I

23

Atezolizumab + Cobitinib

–

72%*

PR: 17%

Avelumab

 MCC

JAVELIN

II

88

Avelumab

–

–

31.8

CR: 9.1%; PR: 22.7%

 UC

Patel et al

Ib

–

Avelumab

1.5

7.4

17

CR: 6%; PR: 11%

 Ovarian cancer

Disis et al

I

–

Avelumab

–

–

9.7

DCR: 54%

Durvalumab

 NSCLC

PACIFIC

III

713

Durvalumab vs. Placebo

16.8 vs. 5.6

–

–

DOR: 72.8% vs. 46.8%

 UC

Powles et al

I/II

191

Durvalumab

1.5

18.2

17.8

CR: 4.7%

 Ovarian cancer

MEDIOLOA

II

32

Durvalumab + Olaparib

–

–

63

–